|
|
|
Bluebird Bio Inc (NASDAQ: BLUE) |
|
|
|
| |
Bluebird Bio Inc Outlook |
On May 9 2024 the Bluebird Bio Inc provided following guidance
bluebird bio Inc. (NASDAQ: BLUE) has reported its first quarter results for 2024, highlighting the Company's operational progress and providing guidance for the year. The company is based in SOMERVILLE, Mass.
Bluebird bio has established a strong foundation in the commercial gene therapy space, with a network of qualified treatment centers (QTCs) that is considered unparalleled. The company has successfully navigated access and reimbursement challenges for patients, and there is a clear demand for their therapies from both patients and healthcare providers.
These achievements have positioned bluebird bio as a leader in the gene therapy industry, with a promising outlook for the future. The company's strategic focus on commercialization and operational excellence has been reflected in its financial performance and market reception.
Moving forward, bluebird bio will continue to advance its innovative gene therapies and expand its reach in the market. With a strong track record of success and a commitment to improving patient outcomes, bluebird bio is well-positioned for continued growth and impact in the gene therapy landscape.
|
On March 26 2024 the Bluebird Bio Inc provided following guidance
he Company provided guidance for 2024, including:
- Expected total revenue of $180 million to $200 million, primarily driven by sales of ZYNTEGLO and SKYSONA
- Continued investment in RandD, with projected expenses of $360 million to $380 million
- Operating expenses estimated to be between $550 million to $570 million
- Anticipated net loss of $400 million to $420 million
- Cash, cash equivalents, and marketable securities of approximately $2.5 billion at the end of 2024
bluebird bio also highlighted key operational achievements in 2023, including the successful launch of ZYNTEGLO in Europe and the continued expansion of the SKYSONA commercial launch. The Company emphasized its commitment to advancing its gene therapy pipeline, with multiple programs in clinical development.
Overall, bluebird bio remains focused on bringing transformative gene therapies to patients in need and driving long-term growth and value creation for its shareholders. The Company is optimistic about its future prospects and looks forward to achieving continued success in 2024 and beyond.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
